CG
AZN icon

Colony Group’s AstraZeneca AZN Stock Holding History

Colony Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$1.89M Sell
13,964
-109
-0.8% -$14.9K 0.03% 343
2023
Q2 		$2.01M Buy
14,073
+118
+0.8% +$17.4K 0.03% 343
2023
Q1 		$1.94M Sell
13,955
-1,617
-10% -$218K 0.03% 351
2022
Q4 		$2.11M Buy
15,572
+4,242
+37% +$532K 0.03% 367
2022
Q3 		$1.24M Buy
11,330
+299
+3% +$37.9K 0.02% 400
2022
Q2 		$1.46M Buy
11,031
+2,028
+23% +$266K 0.03% 371
2022
Q1 		$1.2M Buy
9,003
+176
+2% +$21.1K 0.02% 445
2021
Q4 		$1.03M Buy
8,827
+1,010
+13% +$119K 0.02% 443
2021
Q3 		$939K Buy
7,817
+335
+4% +$39K 0.02% 435
2021
Q2 		$896K Sell
7,482
-886
-11% -$97.2K 0.02% 411
2021
Q1 		$832K Sell
8,368
-575
-6% -$57.8K 0.02% 433
2020
Q4 		$894K Buy
8,943
+3,001
+51% +$318K 0.02% 394
2020
Q3 		$651K Buy
5,942
+645
+12% +$71.7K 0.02% 430
2020
Q2 		$560K Buy
5,297
+408
+8% +$42.1K 0.02% 440
2020
Q1 		$437K Buy
4,889
+191
+4% +$18K 0.01% 481
2019
Q4 		$468K Buy
4,698
+194
+4% +$18.3K 0.01% 545
2019
Q3 		$401K Sell
4,504
-296
-6% -$25.7K 0.01% 532
2019
Q2 		$396K Sell
4,800
-966
-17% -$75.7K 0.01% 551
2019
Q1 		$466K Buy
+5,766
New +$454K 0.02% 412
2016
Q1 		– Sell
-9
Closed -$1K – 276
2015
Q4 		$1K Hold
9
– – ﹤0.01% 721
2015
Q3 		$1K Hold
9
– – ﹤0.01% 788
2015
Q2 		$1K Sell
9
-900
-99% -$61.6K ﹤0.01% 694
2015
Q1 		$62K Sell
909
-8,208
-90% -$570K 0.01% 399
2014
Q4 		$642K Buy
9,117
+995
+12% +$71.2K 0.07% 229
2014
Q3 		$580K Buy
8,122
+7,213
+794% +$528K 0.07% 219
2014
Q2 		$68K Hold
909
– – 0.01% 305
2014
Q1 		$59K Sell
909
-240
-21% -$15.5K 0.01% 310
2013
Q4 		$68K Buy
+1,149
New +$62.4K 0.01% 297

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Colony Group's AZN Position: Q3 2023 in Review

Colony Group reduced its AstraZeneca (AZN) stake by 0.77% in Q3 2023, selling an estimated $14.9K and leaving 13,964 shares worth $1.89M. The position accounts for 0.03% of the portfolio, ranked #343.

Colony Group first reported a position in AZN in Q4 2013 and has held it in 28 quarters since. The position peaked at $2.11M in Q4 2022. 1,075 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

  • Colony Group held 13,964 shares of AstraZeneca worth $1.89M as of Q3 2023.
  • Colony Group sold 109 AstraZeneca shares in Q3 2023, an estimated $14.9K.
  • AstraZeneca made up 0.03% of Colony Group's portfolio in Q3 2023, its #343 holding.
  • Colony Group first reported a position in AstraZeneca in Q4 2013 and has held it in 28 quarters since.
  • Colony Group's AstraZeneca position peaked at $2.11M in Q4 2022.
  • 1,075 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.